Filing Overview
MedTech Acquisition Corporation, which intends to be renamed TriSalus Life Sciences, Inc. upon completion of its proposed business combination, filed this Form 8-K on July 6, 2023, reporting events occurring July 4–5, 2023. The filing concerns the pending merger with TriSalus Life Sciences, Inc., related financing commitments, and amendments to transaction documents. It does not provide a new operating-period income statement or balance sheet for TriSalus.
Key Financial and Transaction Metrics
- Additional subscribers agreed to purchase 2,229,500 shares of Series A Convertible Preferred Stock at $10.00 per share, for aggregate commitments of $22.295 million.
- Initial subscribers had previously committed $17.855 million for 1,785,502 shares.
- Total reported preferred-stock subscriptions therefore equal 4,015,002 shares and $40.150 million, subject to closing conditions.
- Each preferred share is initially convertible into one share of common stock.
- The preferred stock and related conversion shares will be issued in unregistered offerings relying on Section 4(a)(2) of the Securities Act and/or Regulation D.
- No revenue, profit, cash flow, margin, debt, liquidity, or operating-performance figures are reported in this filing.
Material Changes and Agreements
- On July 5, 2023, the parties amended the merger agreement to update the form of amended and restated bylaws that will become effective immediately before the business combination.
- The additional subscription agreements were executed on July 4, 2023 and are substantially similar to the initial subscription agreements, with updates reflecting common-stock redemptions and the Sponsor’s conversion of 6,249,999 Class B shares into Class A shares.
- The preferred-stock financing is expected to close concurrently with the business combination and remains subject to specified conditions, including filing the Series A certificate of designations with Delaware.
- The Company and MedTech Acquisition Sponsor LLC terminated the previously disclosed backstop letter agreement because Sponsor-related parties and designees subscribed for at least $2.0 million of preferred stock.
- Investors will receive registration rights for common shares issuable upon conversion and for shares issued as payment of annual dividends. The Company must generally file a resale registration statement within 30 days after closing and seek effectiveness within 90 days, or 120 days if reviewed by the SEC.
Outlook, Risks, and Unusual Items
The Form S-4 registration statement related to the business combination was not yet effective as of the filing. Completion remains subject to stockholder approval, minimum-cash conditions after redemptions, regulatory approvals, satisfaction of financing conditions, and other customary closing requirements. The filing provides no operating guidance or quantified forecast for TriSalus.
- The merger may not close, may be delayed, or may terminate before completion.
- Financing proceeds may be lower than anticipated if subscription conditions are not satisfied or if transaction conditions fail.
- Minimum cash may be affected by additional redemptions by public stockholders.
- Risks include Nasdaq listing requirements, financing needs, reimbursement changes affecting TriSalus products, legal proceedings, transaction costs, disruption to operations, and failure to realize projected benefits.
- The preferred-stock financing is contingent rather than reported as completed cash proceeds in this filing.
Investor Verification Checklist
- Verify the final effectiveness of the Form S-4 and the date and outcome of the stockholder vote.
- Confirm whether the merger and preferred-stock financing closed and the amount of cash actually received.
- Review the final Series A certificate of designations, including dividend, conversion, voting, liquidation, and other economic terms.
- Reconcile actual public-stockholder redemptions and the resulting minimum cash and capitalization.
- Review subsequent filings for the final share count, dilution, Nasdaq listing status, and registration-statement effectiveness.
- Obtain TriSalus’s historical and pro forma financial statements, since this Form 8-K does not provide current operating metrics.